NBIXNeurocrine Biosciences, Inc.
Is the business good?
A genuinely good business: earnings fully cash-backed (1.5×) and margins widening.
Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.
Operating profit is fully backed by cash. Conversion is worsening vs a year ago.
Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.
Margin-driven, fat margins on slower asset turns. ROE 17% = margin × turnover × leverage.
Unless marked, from derived.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is NBIX?
Neurocrine Biosciences, Inc. earns 19% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
Return on invested capital · cost of capital 9.0% · 10 points above what the capital costs: growth creates value
- Operating margin
- 24%
Operating margin · Drug Manufacturers - Specialty & Generic median 11% · 12 months to Q2 2026
- Cash conversion
- 1.51×
Cash conversion · 1.73× a year ago · operating cash flow covers the operating profit after tax
- Share count, year on year
- +3.2%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2020 | 16% |
| FY2021 | 9.0% |
| FY2022 | 17% |
| FY2023 | 13% |
| FY2024 | 24% |
| FY2025 | 22% |
Details›
- Gross margin12 months to Q2 2026
- 98%
- Operating margin12 months to Q2 2026
- 24%
- Net margin12 months to Q2 2026
- 21%
- Free cash flow margin
- 26%
- R&D as % of revenue
- 34%
- Revenue, trailing twelve months
- $3.37B
- Free cash flow, trailing twelve months
- $866M
- Net income, trailing twelve months
- $706M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 19%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Drug Manufacturers, Specialty & Generic
Ranks #6 of 41 by RyuScore